Psychedelics continue to garner attention as possible treatments for diverse mental health conditions. Now, Compass Pathways (NASDAQ: CMPS) will undertake a study to evaluate psilocybin’s effects on autistic adults.
The study, named Psilaut, is being co-sponsored by the Institute of Psychiatry, Psychology & Neuroscience at King’s College London and the South London and Maudsley NHS Foundation Trust. Forty autistic and 30 non-autistic adults will be enrolled at the double-blind, randomized placebo-controlled Psilaut.
